BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8166723)

  • 1. Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter.
    Loflin PT; Hochhauser D; Hickson ID; Morales F; Zwelling LA
    Biochem Biophys Res Commun; 1994 Apr; 200(1):489-96. PubMed ID: 8166723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
    Fraser DJ; Brandt TL; Kroll DJ
    Mol Pharmacol; 1995 Apr; 47(4):696-706. PubMed ID: 7723730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP; Brown GA; Goldenberg GJ
    Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
    Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
    Harker WG; Slade DL; Parr RL; Holguin MH
    Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity.
    Constantinou A; Henning-Chubb C; Huberman E
    Cancer Res; 1989 Mar; 49(5):1110-7. PubMed ID: 2537141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle-dependent regulation of the mouse DNA topoisomerase IIalpha gene promoter.
    Adachi N; Kobayashi M; Koyama H
    Biochem Biophys Res Commun; 1997 Jan; 230(1):105-9. PubMed ID: 9020022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and regulation of the meprin beta gene in human cancer cells.
    Matters GL; Bond JS
    Mol Carcinog; 1999 Jul; 25(3):169-78. PubMed ID: 10411143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
    Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
    Mo YY; Beck WT
    Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
    Lee CH; Liu M; Sie KL; Lee MS
    Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase II alpha phosphorylation.
    Constantinou AI; Vaughan AT; Yamasaki H; Kamath N
    Cancer Res; 1996 Sep; 56(18):4192-9. PubMed ID: 8797591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
    Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
    Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
    Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation.
    Kuprash DV; Osipovich OA; Pokholok DK; Alimzhanov MB; Biragyn A; Turetskaya RL; Nedospasov SA
    J Immunol; 1996 Apr; 156(7):2465-72. PubMed ID: 8786306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.